Alterations of RAS pathway members are also very frequent in acral melanomas, being detected in 87% of these patients: NRAS (17%), Aurora Kinase A (AURKA) (37.5%), Ciclin D1 (CCND1) or telomerase reverse transcriptase (TERT, 31%), and RAS (25%) [70]. The gene discussed is AURKA; the disease is acral lentiginous melanoma.